In the same model, LPAR1, LPAR3, and ATX-expression levels are upregulated upon disease; administration of the LPAR1/LPAR3 antagonist BMS002 ameliorates glomerular filtration and renal fibrosis, while it reduces macrophage infiltration and podocyte loss [18]. This evidence concerns the gene ENPP2 and renal fibrosis.